Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 25, 2011, Pages 2611-2618

  Loureiro, A I ^a   Fernandes Lopes, C ^a   Wright, L C ^a   Soares da Silva, P ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; Eslicarbazepine; Eslicarbazepine acetate; LC MS MS; Oxcarbazepine; R licarbazepine

Indexed keywords

ANTIEPILEPTIC DRUGS; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; LC-MS/MS; OXCARBAZEPINE; R-LICARBAZEPINE;

ELECTROSPRAY IONIZATION; EXTRACTION; HEXANE; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PLASMA (HUMAN); PLASMAS; STABILITY CRITERIA; VOLATILE FATTY ACIDS;

PLASMA STABILITY;

10,11 DIHYDROCARBAMAZEPINE; 2 PROPANOL; ALCOHOL; DRUG METABOLITE; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; LICARBAZEPINE; OXCARBAZEPINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOSELECTIVITY; FLOW RATE; FREEZE THAWING; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CARBAMAZEPINE; CHROMATOGRAPHY, LIQUID; DIBENZAZEPINES; DRUG STABILITY; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 84860400193     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.07.019     Document Type: Article

References (13)

1. Elger C., Bialer M., Cramer J.A., Maia J., Almeida L., Soares-da-Silva P. Epilepsia 2007, 48:497.
2. Elger C., Halasz P., Maia J., Almeida L., Soares-da-Silva P. Epilepsia 2009, 50:454.
3. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J., Soares-da-Silva P. Acta Neurol. Scand. 2009, 120:281.
4. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Eur. J. Clin. Pharmacol. 2008, 64:267.
5. Alves G., Figueiredo I., Castel-Branco M., Loureiro A., Falcao A., Caramona M. Anal. Chim. Acta 2007, 596:132.
6. Fortuna A., Sousa J., Alves G., Falcao A., Soares-da-Silva P. Anal. Bioanal. Chem. 2010, 397:1605.
7. Alves G., Figueiredo I., Castel-Branco M., Loureiro A., Fortuna A., Falcao A., Caramona M. Biomed. Chromatogr. 2007, 21:1127.
8. Mone M.K., Chandrasekhar K.B. J. Pharm. Biomed. Anal. 2011, 54:248.
9. Mazzucchelli I., Franco V., Fattore C., Marchiselli R., Perucca E., Gatti G. Ther. Drug Monit. 2007, 29:319.
10. FDA Guidance For Industry, 2001.
11. Savoie N., Garofolo F., van Amsterdam P., Bansal S., Beaver C., Bedford P., Booth B.P., Evans C., Jemal M., Lefebvre M., Silva A.L.L., Marini J.C., Massé R., Mawer L., Ormsby E., Rocci M.L., Viswanathan C.T., Wakelin-Smith J., Welink J., White J.T., Woolf E. Bioanalysis 2010, 2:1945.
12. Alves G., Figueiredo I., Falcao A., Castel-Branco M., Caramona M., Soares-da-Silva P. Chirality 2008, 20:796.
13. Volosov A., Sintov A., Bialer M. Ther. Drug Monit. 1999, 21:219.